Provided by Tiger Fintech (Singapore) Pte. Ltd.

PAVmed

0.7700
-0.0201-2.54%
Post-market: 0.77000.00000.00%17:23 EDT
Volume:44.80K
Turnover:34.69K
Market Cap:13.16M
PE:1.55
High:0.7900
Open:0.7600
Low:0.7600
Close:0.7901
Loading ...

BRIEF-Pavmed Inc Files For Mixed Shelf Offering Of Up To $125 Million

Reuters
·
21 Dec 2024

PAVmed Inc: Files for Mixed Shelf Offering of up to $125 Mln

THOMSON REUTERS
·
21 Dec 2024

Lucid Diagnostics partners for esophageal precancer detection for firefighters

TIPRANKS
·
19 Dec 2024

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

PR Newswire
·
19 Dec 2024

Lucid announces publication on EsoGuard in peer-reviewed journal Medicina

TIPRANKS
·
11 Dec 2024

Prospective Clinical Utility Study of Lucid Diagnostics' Esoguard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

THOMSON REUTERS
·
11 Dec 2024

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

PR Newswire
·
11 Dec 2024

PAVmed Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
09 Dec 2024

PAVmed Inc : Ascendiant Capital Markets Cuts Target Price to $19 From $21

THOMSON REUTERS
·
09 Dec 2024

Lucid Diagnostics completes convertible debt refinancing

TIPRANKS
·
03 Dec 2024

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

THOMSON REUTERS
·
03 Dec 2024

Press Release: Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

Dow Jones
·
03 Dec 2024

Lucid Diagnostics submits clinical evidence for EsoGuard Esophagea DNA test

TIPRANKS
·
20 Nov 2024

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

PR Newswire
·
20 Nov 2024

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

PR Newswire
·
18 Nov 2024

PAVmed Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.
·
17 Nov 2024

PAVmed Positioned for Growth Despite Q3 Revenue Miss: Buy Rating Affirmed by Anthony Vendetti

TIPRANKS
·
16 Nov 2024

PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring

GuruFocus.com
·
15 Nov 2024

PAVmed Q3 2024 Adj. EPS $(0.54)

Benzinga
·
14 Nov 2024

PAVmed: Ongoing Initiatives Position PAVmed to Preserve Nasdaq Listing

THOMSON REUTERS
·
14 Nov 2024